First MRX and now OMPI: evidently VRX wants to be a serious competitor to AGN in aesthetic medicine. It’s not hard to see why: most patients for these products are affluent and self-pay, and the business is a beneficiary of The Global Demographic Tailwind.
Market Data 
Markets 
AI
